fluoxetine has been researched along with enalapril in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (11.11) | 18.7374 |
1990's | 2 (22.22) | 18.2507 |
2000's | 2 (22.22) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Griffin, JH; Hahn, SM | 1 |
Grupp, LA; Perlanski, E; Stewart, RB | 1 |
Almdal, TP; Christensen, O; Sørensen, HA | 1 |
Boersma, C; Bos, JM; de Jong-van den Berg, LT; Klok, RM; Naunton, M; Postma, MJ; van den Berg, PB | 1 |
1 review(s) available for fluoxetine and enalapril
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for fluoxetine and enalapril
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Comment: fluoxetine adverse effects and drug interactions.
Topics: Adult; Depressive Disorder; Drug Interactions; Enalapril; Female; Fluoxetine; Humans; Imipramine | 1991 |
Attenuation of alcohol intake by a serotonin uptake inhibitor: evidence for mediation through the renin-angiotensin system.
Topics: Alcohol Drinking; Animals; Body Weight; Enalapril; Fluoxetine; Male; Rats; Rats, Inbred Strains; Reference Values; Renin-Angiotensin System | 1988 |
[Adverse effects of selective serotonin uptake inhibitors. Hyponatremia caused by Schwartz-Bartter syndrome].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antidepressive Agents, Second-Generation; Antihypertensive Agents; Enalapril; Female; Fluoxetine; Humans; Hyponatremia; Inappropriate ADH Syndrome; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1996 |
Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for the Netherlands.
Topics: Anti-Ulcer Agents; Antidepressive Agents, Second-Generation; Antihypertensive Agents; Drug Costs; Drugs, Generic; Enalapril; Fluoxetine; Humans; Netherlands; Patents as Topic; Ranitidine; Reimbursement Mechanisms | 2005 |